Dr. Lily O. Otolorin
Overview
Lily Otolorin is a Palliative Medicine provider in Alexandria, Virginia. Her top area of expertise is ALK-Positive Non-Small Cell Lung Cancer.
Her clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Graduate Institution
Residency
Specialties
Licenses
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- PPO
- HMO
- HMO
- POS
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Saluja Medical Assoc
Vijay Sharma is a primary care provider, practicing in Palliative Medicine in Baltimore, Maryland. Dr. Sharma is highly rated in 34 conditions, according to our data. His top areas of expertise are Stroke, Necrosis, Dementia, Cerebral Artery Bypass Surgery, and Thrombectomy.
Skip Viragh Outpatient Cancer Center
Ilene S. Browner, M.D. specializes in geriatric oncology. Dr. Browner is highly rated in 23 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Endoscopy.
Sinai Hospital Of Baltimore
Kenneth Miller is a Palliative Medicine provider in Baltimore, Maryland. Dr. Miller is highly rated in 15 conditions, according to our data. His top areas of expertise are Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Small Cell Lung Cancer (SCLC).
Frequently Asked Questions about Dr. Lily O. Otolorin
How do I make an appointment with Dr. Lily O. Otolorin?
You can book an appointment with Dr. Lily O. Otolorin by calling their office at 571-298-3314. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Lily O. Otolorin a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lily O. Otolorin is classified as an Experienced expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Lily O. Otolorin specialize in?
While Dr. Lily O. Otolorin is a Palliative Medicine, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Palliative Medicine.
Does Dr. Lily O. Otolorin participate in research or clinical trials?
Yes. Dr. Lily O. Otolorin has published 1 articles and abstracts on conditions like ALK-Positive Non-Small Cell Lung Cancer. You can view a list of Dr. Lily O. Otolorin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Lily O. Otolorin accept my insurance?
Dr. Lily O. Otolorin accepts most major insurance plans, including Cigna and Innovation Health. We recommend calling the office directly at 571-298-3314 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- ALK-Positive Non-Small Cell Lung CancerDr. Otolorin isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.